This article is a correction to:
Assessing the Function of the ZFP90 Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes
Tingting Zhu1,2†
Yuandi Huang1†
Danfeng Qian3†
Yuming Sheng1
Chaowen Zhang1
Shirui Chen1
Hui Zhang1
Hui Wang1
Xuejun Zhang1
Junlin Liu4*
Changhai Ding2,5,6*
Lu Liu1,7*- 1Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
- 2Department of Rheumatology and Immunology, Arthritis Research Institute, The First Affiliated Hospital of Anhui Medical University, Hefei, China
- 3Department of Dermatology, Lu’an People’s Hospital, Lu’an, China
- 4Department of Dermatology, The Second Affiliated Hospital, Hainan Medical University, Haikou, China
- 5Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Zhujiang, China
- 6Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
- 7Department of Medical and Molecular Genetics, King’s College London, London, United Kingdom
A Corrigendum on
Assessing the Function of the ZFP90 Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes
By Zhu T, Huang Y, Qian D, Sheng Y, Zhang C, Chen S, Zhang H, Wang H, Zhang X, Liu J, Ding C and Liu L (2021). Front. Immunol. 12:611515. doi: 10.3389/fimmu.2021.611515
In the original article, there were mistakes in Figures 1, 3, 4 as published. The number of CC genotype is not 10 but 2 in the legend of Figure 1A. The SNP ID is not rs2297550 but rs1170426 and the number of CT genotype is not 33 but 34 in the legend of Figure 1B. The number of CT genotype is not 33 but 34 in the label of Figure 1B. In Figure 3, the legends of Figures 3B, 3C were inverted. In Figure 4B, the label of arthritis is not FDR p = 0.004 but FDR p = 0.020 as shown in Table 3. The corrected Figures 1, 3, 4 appear below.
FIGURE 1
Figure 1 (A) The effect of rs1170426 on ZFP90 mRNA expression levels in PBMCs from healthy controls. Of the 126 controls, 2 individuals with CC, 38 with CT and 86 with TT were analyzed. The group with “CC” homozygous has the lowest expression levels (P = 0.006). (B) The effect of rs1170426 on ZFP90 mRNA expression levels in PBMCs from SLE cases. Of the 117 cases, 4 individuals with CC, 34 with CT and 79 with TT were analyzed. The expression did not significantly correlate with genotype of rs1170426 (P = 0.548). (C–F) The effect of rs1170426 on ZFP90 mRNA expression levels in CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD14+ monocytes from other 110 healthy controls. Of the 110 controls, 3 individuals with CC, 23 with CT and 84 with TT were analyzed. ZFP90 expression levels of samples with risk allele “C” of rs1170426 were significantly decreased in CD8+ T cells (P = 0.003).
FIGURE 3
Figure 3 (A)The epigenome annotation results of rs1170426 in T cells (green), B cells (red) and PBMCs (orange). The signal can be found in T cells and PBMCs, while not in B cells. (B) Compared the ZFP90 mRNA expression levels between SLE cases (n = 117, red) and healthy controls (n = 126, green) in PBMCs. The expression levels were lower in cases than in healthy controls (P =2.78E-9). (C) The ZFP90 mRNA expression levels in four kinds of immune cells were remarkably different (P = 2.001E-56) and were higher in T cells.
FIGURE 4
Figure 4 (A) The ZFP90 mRNA expression levels were lower (FDR p =0.004) in cases with serositis than those without. (B) The levels were lower (FDR p = 0.020) in cases with arthritis than those without. (C) The levels were lower (FDR p = 0.021) in cases with hematologic involvement than those without. (D) The levels were lower (FDR p = 0.005) in cases with increased CRP than those without.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: ZFP90, single nucleotide polymorphism, systemic lupus erythematosus, eQTL, SLE drug target genes
Citation: Zhu T, Huang Y, Qian D, Sheng Y, Zhang C, Chen S, Zhang H, Wang H, Zhang X, Liu J, Ding C and Liu L (2022) Corrigendum: Assessing the Function of the ZFP90 Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes. Front. Immunol. 13:840847. doi: 10.3389/fimmu.2022.840847
Received: 21 December 2021; Accepted: 03 February 2022;
Published: 18 February 2022.
Edited and reviewed by:
Jeehee Youn, Hanyang University, South KoreaCopyright © 2022 Zhu, Huang, Qian, Sheng, Zhang, Chen, Zhang, Wang, Zhang, Liu, Ding and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lu Liu, liulu8887@163.com; Changhai Ding, changhai.ding@utas.edu.au; Junlin Liu, liujunlin0759@163.com; lu.2.liu@kcl.ac.uk
†These authors have contributed equally to this work